10-Q: UroGen Pharma Q2 2025: Zusduri Approved, Losses Widen

UroGen Pharma reported increased revenue from Jelmyto sales but wider net losses in Q2 2025, alongside the significant FDA approval of Zusduri and progress in its pipeline.

Summary

• Net loss for the six months ended June 30, 2025, was $93.8 million, compared to $65.7 million for the same period in 2024, representing a significant increase in losses.
• Revenue for the six months ended June 30, 2025, increased to $44.5 million from $40.6 million in the prior year, primarily driven by increased sales volume of Jelmyto.
• Operating expenses rose substantially, with Research and Development expenses increasing by $7.9 million to $38.8 million, and Selling, General and Administrative expenses increasing by $14.0 million to $50.0 million for the six months ended June 30, 2025.
• The FDA approved Zusduri (mitomycin) for intravesical solution on June 12, 2025, for recurrent low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC), with commercial promotion beginning in late June 2025 and product availability by July 1, 2025.
• The estimated annual treatable population for low-grade intermediate risk NMIBC in the United States is approximately 82,000 patients, with a total addressable market opportunity for Zusduri potentially exceeding $5.0 billion.
• Cash and cash equivalents, along with marketable securities, totaled $161.6 million as of June 30, 2025, down from $236.7 million as of December 31, 2024.
• The company's accumulated deficit grew to $900.0 million as of June 30, 2025.
• The repayment period for the Pharmakon loan was extended by one year following Zusduri's FDA approval, with principal repayments now commencing in Q2 2027.
• The company does not intend to draw down the fourth tranche of $75.0 million from the Pharmakon loan, which became available upon Zusduri's FDA approval.

Sentiment

Score: 4

Explanation: While the FDA approval of Zusduri is a major positive and opens a significant market, the company's financial performance shows widening losses and a substantial decrease in cash reserves, indicating a high burn rate. The long-term potential is strong, but the immediate financial health presents challenges and requires careful monitoring of capital management and commercialization success.

Positives

• FDA approval of Zusduri on June 12, 2025, for recurrent low-grade intermediate risk NMIBC, marking a significant milestone and the first and only FDA-approved non-surgical treatment for this condition.
• Increased revenue from Jelmyto sales, rising to $44.5 million for the six months ended June 30, 2025, demonstrating continued commercial traction for the product.
• Successful completion of patient enrollment for the Phase 3 UTOPIA trial for UGN-103 in July 2025, with topline data expected by the end of 2025.
• Initiation of a Phase 3 trial for UGN-104 in low-grade UTUC in June 2025, following FDA acceptance of its IND in February 2025.
• Extension of the Pharmakon loan repayment period by one year, with principal repayments now scheduled to begin in Q2 2027, providing additional financial flexibility.
• Long-term durability of response data for Jelmyto (median DOR of 47.8 months) and Zusduri (80.6% DOR at 18 months for CR patients) from follow-up studies, supporting product efficacy.

Negatives

• Net loss significantly widened to $93.8 million for the six months ended June 30, 2025, compared to $65.7 million in the prior year, indicating increased operational burn.
• Operating expenses increased substantially, with R&D up by $7.9 million and SG&A up by $14.0 million for the six-month period, driven by commercial preparation for Zusduri and pipeline development.
• Cash and cash equivalents, combined with marketable securities, decreased from $236.7 million at December 31, 2024, to $161.6 million at June 30, 2025, reflecting significant cash usage.
• Accumulated deficit increased to $900.0 million, highlighting continued unprofitability since inception.
• Cost of revenue increased by $1.9 million, partly due to a higher unit cost of Jelmyto and an inventory write-off.
• The company is highly dependent on two customers for Jelmyto sales, with the largest customer comprising over 75% of product sales for the three months ended June 30, 2025, posing customer concentration risk.

Risks

• The company may require additional financing to fund operations and achieve goals, and failure to obtain this capital could force delays or termination of product development and commercialization efforts.
• High dependence on the successful commercialization of Jelmyto and Zusduri, with risks related to market acceptance, physician adoption, and competition.
• Limited organizational experience in marketing and distributing products, posing challenges for successful commercialization of Jelmyto and Zusduri.
• Market opportunities for products may be smaller than anticipated or limited to specific patient populations, potentially hindering commercial success.
• Significant competition from other pharmaceutical companies and existing surgical standards of care, including potential generic competition for Jelmyto from Teva Pharmaceuticals.
• Clinical drug development is lengthy, expensive, and uncertain, with no guarantee that current or future clinical trials will succeed or meet timelines.
• Risk of undesirable side effects or adverse events from products, which could prevent marketing approval, lead to market withdrawal, or increase commercialization costs.
• Reliance on third-party subcontractors and single-source suppliers for raw materials and manufacturing, posing risks of supply disruptions, increased costs, and regulatory non-compliance.
• Exposure to international trade policies, including tariffs, sanctions, and trade barriers, which could adversely affect business, financial condition, and supply chain.
• Potential for product liability lawsuits, which could result in substantial liabilities, limit commercialization, and harm reputation.
• Inability to attract and retain senior management and key personnel, which could impede successful product development and commercialization.
• Information technology systems or data, or those of third parties, being compromised, leading to regulatory investigations, litigation, financial losses, and operational disruptions.
• Geopolitical, economic, and military instability in Israel, where significant operations are located, could adversely affect results and operations.
• Uncertainty regarding the enforceability of non-compete covenants with employees under applicable employment laws.
• Potential for future developmental and regulatory difficulties, including changes in regulatory requirements or delays in obtaining approvals.
• Healthcare reforms and legislation, including those related to drug pricing and reimbursement, could adversely affect product coverage, reimbursement, and profitability.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could result in adverse tax consequences for U.S. shareholders.
• Changes to tax laws or disagreements with tax authorities could increase tax liabilities or reduce expected benefits.
• Limitations on the ability to use U.S. net operating loss carryforwards and other tax attributes due to ownership changes.

Future Outlook

The company expects to continue incurring losses and negative net cash flows from operating activities as it executes its strategy, including the commercial launch of Zusduri, continued commercialization of Jelmyto, and further research and development activities for its pipeline candidates. Management believes it has sufficient cash and cash equivalents to fund operations beyond one year from the financial statement issuance date. Future research and development expenses are expected to increase as clinical programs progress and new product candidates are identified and developed. The company plans to finance future cash needs through a combination of equity or debt financings and collaboration arrangements.

Management Comments

• We believe Zusduri has the potential to become the new standard of care for recurrent low-grade intermediate risk NMIBC as the first and only FDA-approved non-surgical treatment.
• We are focused on changing the way urothelial cancers are treated, an area in which there have been no significant advancements in recent years.
• We are committed to helping patients access Jelmyto.
• We initiated promotion of Zusduri in the United States in late June 2025 with product available by July 1, 2025.
• We expect topline CR data for UGN-103 by the end of 2025, with an NDA submission projected for 2026 and potential FDA approval and commercial launch in 2027.
• We do not intend to draw down the fourth tranche of $75.0 million from the Pharmakon loan.

Industry Context

UroGen Pharma operates in the highly competitive biotechnology industry, specifically focusing on urothelial and specialty cancers, an area with limited significant advancements in recent years. The company's proprietary RTGel reverse-thermal hydrogel technology is a key differentiator, designed to improve therapeutic profiles by enabling longer exposure of urinary tract tissue to medications. This technology aims to provide non-surgical treatment options, contrasting with the traditional surgical standard of care for conditions like low-grade UTUC and NMIBC. The recent FDA approval of Zusduri positions UroGen as a pioneer in non-surgical treatment for recurrent low-grade intermediate risk NMIBC, potentially disrupting the existing market dominated by surgical procedures. The company's pipeline, including UGN-103, UGN-104, UGN-301, and UGN-501, indicates a strategic focus on expanding its uro-oncology portfolio and leveraging its RTGel platform for various indications. The industry faces challenges such as lengthy and expensive clinical development, intense competition from established pharmaceutical companies, and evolving regulatory and reimbursement landscapes.

Comparison to Industry Standards

• The company's RTGel technology, which allows for significantly extended dwell time of active drugs (e.g., mitomycin for 6 hours compared to 5 minutes for standard aqueous formulations), offers a distinct advantage over traditional water-based formulations in local drug delivery for urinary tract cancers.
• Zusduri is positioned as the first and only FDA-approved non-surgical treatment for recurrent low-grade intermediate risk NMIBC, directly challenging the existing standard of care, transurethral resection of bladder tumor (TURBT), which is a surgical procedure.
• The estimated total addressable market opportunity for Zusduri in recurrent low-grade intermediate risk NMIBC is potentially over $5.0 billion, indicating a significant market potential compared to the current treatment landscape.
• The company faces competition from various pharmaceutical companies developing drugs in urology and uro-oncology, including AADi LLC, Aura Biosciences, Inc., Biocancell Ltd., Bristol Myers Squibb, CG Oncology Inc., enGene Holdings, Ferring Pharmaceuticals (with Adstiladrin for high-risk BCG-unresponsive NMIBC), FKD Therapies Oy, GSK, ImmunityBio, ImPact Biotech Ltd., Johnson & Johnson, LIPAC Oncology, Merck Sharp & Dohme Corp, Pfizer, Prokarium, Protara Therapeutics, Relmada Therapeutics, Roche, Samyang Biopharma, SURGE Therapeutics, Trigone Pharma, Tyra Biosciences, Viralytics Limited and Vyriad.
• The ongoing patent infringement lawsuit against Teva Pharmaceuticals, Inc. regarding a generic version of Jelmyto highlights the competitive pressure from generic manufacturers, a common challenge in the pharmaceutical industry as products approach patent expiry or loss of exclusivity.

Corporate Governance

Legal Proceedings

• On April 2, 2024, UroGen Pharma Ltd. filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
• The lawsuit seeks a permanent injunction to prevent market entry of Teva's generic version of Jelmyto prior to the expiry of these patents, which are listed in the FDA's Orange Book and expire in January 2031.
• On May 19, 2025, the company filed an amended complaint in this action, adding U.S. Patent Number 12,268,745 to the litigation.
• The matter is scheduled for a bench trial in October 2026.
• If the company is unsuccessful in securing the requested court relief, Jelmyto may face immediate competition from an FDA-approved generic product after its orphan drug exclusivity expires in April 2027.

Related Party Transactions

• In connection with the acquisition of certain assets from IconOVir Bio, Inc. on February 14, 2025, entities affiliated with Arie Belldegrun, M.D., the Chair of the Board of Directors of the Company, held promissory notes of IconOVir. These entities may receive approximately 28.3% of the purchase price paid to IconOVir pursuant to the Asset Purchase Agreement.

Stakeholder Impact

• **Shareholders**: Experience dilution from past equity offerings and potential future capital raises. The widening net losses and decreasing cash reserves could negatively impact share price, while the FDA approval of Zusduri offers significant long-term growth potential.
• **Employees**: The company continues to expand its workforce, particularly in commercial operations for Zusduri, indicating job growth. Share-based compensation plans are in place to incentivize and retain talent. However, geopolitical risks in Israel could impact Israeli employees.
• **Customers (Healthcare Providers & Patients)**: Benefit from the availability of Jelmyto and the newly approved Zusduri, offering non-surgical treatment options for urothelial cancers. The company's focus on market access and reimbursement aims to ensure product accessibility.
• **Suppliers**: The company relies on single-source suppliers for critical raw materials (e.g., mitomycin API, hydrogel), posing concentration risk. Any disruptions could impact product availability.
• **Creditors (Pharmakon & RTW Investments)**: The extension of the Pharmakon loan repayment period provides more time for the company to generate revenue. RTW Investments receives tiered payments based on product sales, aligning their interests with commercial success.

Next Steps

• Commercial launch and continued promotion of Zusduri in the United States, with product available by July 1, 2025.
• Completion of the ongoing ENVISION trial for Zusduri to further characterize its clinical benefit, with annual updates on durability of response (DOR) for patients with ongoing complete responses (CRs) until 63 months after first instillation or other endpoints.
• Expected topline complete response (CR) data for the Phase 3 UTOPIA trial of UGN-103 by the end of 2025.
• Projected New Drug Application (NDA) submission for UGN-103 in 2026, with potential FDA approval and commercial launch in 2027.
• Continued Phase 3 trial for UGN-104 in low-grade UTUC, initiated in June 2025.
• Ongoing IND-enabling studies for UGN-501, with a Phase 1 clinical study planned for 2026.
• Reporting updated data for the UGN-301 Phase 1 study in 2025.
• Continued efforts to help patients access Jelmyto and ensure seamless integration into physician practices.
• Ongoing legal proceedings against Teva Pharmaceuticals, Inc. for patent infringement, with a bench trial scheduled for October 2026.

Key Dates

Recommendation

The FDA approval of Zusduri is a transformative event, opening a multi-billion dollar market opportunity and validating UroGen's RTGel technology. This significantly de-risks a key pipeline asset and provides a strong foundation for future growth. However, the company's financial performance shows widening net losses and a substantial decrease in cash reserves, indicating a high burn rate as it invests heavily in commercialization and R&D. While management believes it has sufficient cash for over a year, continued profitability is uncertain. The ongoing patent litigation for Jelmyto also presents a material risk. Given the significant upside potential from Zusduri's launch balanced against the increasing financial burn and execution risks, a 'hold' recommendation is appropriate. Investors should monitor Zusduri's commercial uptake and the company's cash management closely.

Keywords

Biotechnology, Uro-oncology, Jelmyto, Zusduri, NMIBC, UTUC, RTGel, Mitomycin, Clinical Trials, FDA Approval, Pharmaceutical, Drug Development, Oncology, Urology